XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Inclusion Criteria: * ≥18 years of age * Advanced malignant solid tumor patients with a BRAF V600 mutation (limited to melanoma, colorectal cancer, non-small cell lung cancer, or thyroid cancer). * Must have failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Prior treatment with BRAF inhibitors and/or MEK inhibitors is permitted； * At least one measurable lesion (brain metastasis must not be the only measurable lesion) according to Response Evaluation Criteria in Solid Tumours (RECIST v1.1); * ECOG performance status of 0 or 1; * Expected survival ≥ 3 months; * Adequate liver, renal, coagulation, cardiac, and hematologic function. * A negative pregnancy test if female patient is of reproductive potential. * For men and women of reproductive potential, agreement to use an effective contraceptive method from the time of screening and throughout their time on study. * Patients must agree to, and be capable of, adhering to the study visit schedule and all other protocol requirements; * Patients must understand and voluntarily sign the written informed consent form, before the initiation of any study-specific procedures in the trial. Exclusion Criteria: * Active central nervous system (CNS) lesions. However, patients with asymptomatic and brain metastases who received treatment (including targeted brain radiotherapy, surgical treatment, glucocorticoid or other treatments) without disease progr…